Global Breast Cancer Therapeutics Market is valued approximately at USD 19.57 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.16% over the forecast period 2020-2027. Growing incidence of breast cancer due to factors such as excessive exposure to endogenous estrogens, early menarche, late birth and late menopause would have a high effect on the growth of the industry. The technical developments in cancer biology and the introduction of a range of diagnostic and screening programs around the world should drive the company. Growing acceptance of therapeutic drugs due to factors such as the blocking of estrogen from binding to tumor cells, the risk of distant reappearance, the lowering of the risk of reappearance in the breast that had tumor, and the lowering of the risk of developing disease in another breast would stimulate the growth of the industry. The awareness of breast cancer, a growing change towards western lifestyle adoption, a limited breast-feeding period and a growing prevalence of obesity in postmenopausal women would drive industry size. Increased intake of alcohol in women, increased use of hormone replacement therapy (HRT) and oral birth control pills resulting in increased levels of estrogen would increase the size of the company over the forecast period. Growing exposure to certain carcinogens and endocrine disruptors, for example, in the workplace, night shifts result in increased risk, and the global demand is increasing. WHO has reported that breast cancer affects around 2.1 million people per year and is the leading cause of malignancy-related deaths. In 2018, 627,000 women were estimated to have died of breast cancer globally, accounting for 15 % of total deaths. Prohibitive costs associated with the use of breast cancer therapy can impede the growth of the industry. Increasing the cost of early and late-stage disease treatment, continuing care on a per-unit basis, accounting for a significant share of lifetime costs due to the relatively longer survival of breast cancer patients, may further restrict business growth.
The regional analysis of global Breast Cancer Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is anticipated to account for the largest market share in 2018. Development is due to a growing incidence of breast cancer and increased support for R&D across the public and private sectors. Growing elderly population, early-onset breastfeeding and expanded access to cancer care would stimulate industry development. In addition, growing demand for tumor therapy would strongly boost the growth of the industry in the region.
Major market player included in this report are:
AstraZeneca
Bristol-Myers Squibb
Eisai Co. Ltd
Eli Lilly and Company
Genentech
GlaxoSmithKline
Halozyme Inc.
Novartis AG
Pfizer Inc.
Genzyme Corporation
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Hormone Drugs
Chemotherapy Drugs
Targeted Drug Therapy
By Distribution Channel:
Hospitals
Ambulatory Surgical Centers
Clinics
e-commerce
Retail Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of the Global Breast Cancer Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors